Not available
Quote | Agenus Inc. (NASDAQ:AGEN)
Last: | $11.69 |
---|---|
Change Percent: | -3.61% |
Open: | $8.6 |
Close: | $11.69 |
High: | $12.23 |
Low: | $8.45 |
Volume: | 3,354,048 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
News | Agenus Inc. (NASDAQ:AGEN)
A look at the top 10 most actives in the United States Pineapple Energy Inc. (PEGY) rose 20.6% to $0.0626 on volume of 316,091,551 shares Snap Inc. Class A (SNAP) rose 27.6% to $14.55 on volume of 158,621,648 shares PROSHARES TRUST (SQQQ) fell 4.8% to $11.43 on volume of 135,432,504 share...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced an upcoming presentation from the Phase 1b trial of botensilimab in combination with balstilimab (“BOT/BAL”) in patients with relapsed/ref...
Message Board Posts | Agenus Inc. (NASDAQ:AGEN)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $AGEN News Article - Agenus Selected for Late-Breaking Oral Presentation at ESMO-GI | whytestocks | investorshangout | 05/03/2023 6:35:51 PM |
shalbyj: TheStreetReports: AI Biotech Stocks to Watch 2023: $IPA, $ONTX, $AGEN, $PBIO https://www.ma | shalbyj | investorshangout | 04/25/2023 1:37:15 PM |
whytestocks: $AGEN News Article - Agenus Receives Fast Track Designation for Botensilimab and Balsti | whytestocks | investorshangout | 04/17/2023 12:00:59 PM |
whytestocks: $AGEN News Article - Agenus' Botensilimab in Combination with Balstilimab Shows 33% Dur | whytestocks | investorshangout | 03/27/2023 3:10:50 PM |
whytestocks: $AGEN News Article - Best Penny Stocks To Buy Now: 3 To Watch Before Next Week | whytestocks | investorshangout | 03/15/2023 8:20:47 PM |
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Pineapple Energy Inc. (PEGY) rose 20.6% to $0.0626 on volume of 316,091,551 shares Snap Inc. Class A (SNAP) rose 27.6% to $14.55 on volume of 158,621,648 shares PROSHARES TRUST (SQQQ) fell 4.8% to $11.43 on volume of 135,432,504 share...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced an upcoming presentation from the Phase 1b trial of botensilimab in combination with balstilimab (“BOT/BAL”) in patients with relapsed/ref...
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, whic...